45M, trading at A.29 on the ASX. This SniperIQ fundamentals page covers AFT Pharmaceuticals's valuation (P/E 28.1x, P/B 3.8x), profitability (net margin 5.8%), revenue (NZD 257M in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
45M
P/E (TTM)28.1x
Net Margin5.8%
Revenue (FY26)NZD 257M

Full research coverage

Frequently Asked Questions

What is AFT Pharmaceuticals's market cap?

AFT Pharmaceuticals (AFP) has a market capitalization of approximately A

45M, trading at A.29 on the ASX. Market cap moves with the live share price.

What is AFT Pharmaceuticals's P/E ratio?

AFT Pharmaceuticals's trailing twelve-month P/E ratio is 28.1x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is AFT Pharmaceuticals?

AFT Pharmaceuticals runs a net profit margin of 5.8%, a gross margin of 43.4%, and an operating margin of 9.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does AFT Pharmaceuticals generate?

AFT Pharmaceuticals reported revenue of NZD 257M for fiscal year 2026, with net income of NZD 15M and earnings per share (EPS) of 0.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does AFT Pharmaceuticals pay a dividend?

AFT Pharmaceuticals offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is AFT Pharmaceuticals financially healthy?

AFT Pharmaceuticals carries a debt-to-equity ratio of 0.49x and a current ratio of 2.24x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is AFT Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AFT Pharmaceuticals (AFP) the key facts are: market cap A

45M, P/E 28.1x, revenue NZD 257M, 52-week range 2.2-3.37. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track AFT Pharmaceuticals's full fundamentals live

Get AFT Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.